Immunohistochemical Evaluation of GATA-3 in Patients with Urinary Bladder Cancer
1
Department of Basic Sciences, Collage of Dentistry, Kufa, University of Kufa, Kufa, Iraq
2
DEPARTMENT OF GENERAL PATHOLOGY AND FORENSIC MEDICINE, COLLAGE OF MEDICINE, UNIVERSITY OF KUFA, KUFA, IRAQ
Submission date: 2024-01-29
Final revision date: 2024-10-23
Acceptance date: 2024-11-12
Publication date: 2025-01-30
Corresponding author
Randa Saad Hameed
DEPARTMENT OF BASIC SCIENCES, COLLAGE OF DENTISTRY, UNIVERSITY OF KUFA, KUFA, IRAQ
DEPARTMENT OF BASIC SCIENCES, COLLAGE OF DENTISTRY, UNIVERSITY OF KUFA, KUFA, IRAQ
Wiadomości Lekarskie 2024;77(12):2381-2387
KEYWORDS
TOPICS
ABSTRACT
Aim:
Background: urinary bladder cancer is a disturbing malignant disorder which participates about 3% to the recent development of cancer field. The etiology and pathogenesis can be related to environmental and occupational agents. Transformation of normal urothelial cell to a neoplastic one occurs through complicated sequences of molecular proceedings termed as epithelial plasticity. Aims: to analyze expression levels of GATA-3 in bladder tumor tissues and to prove a relation between expression of GATA-3 and clinicopathological characteristics of bladder tumors, including patient age, sex, tumor grade, and muscle invasion.
Material and methods:
Materials and methods: Forty Formalin fixed paraffin embedded FFPE tissue blocks obtained from bladder tumor by transurethral resection are collected from teaching hospitals at Al-Najaf governorate. Those blocks are stained by using hematoxylin and eosin stain. Histopathological features were examined and then immunostained by GATA-3.
Results:
Results: Evaluation of GATA-3 expression in urothelial carcinoma, revealed GATA-3 test was (positive) in thirty-four samples of urothelial carcinoma, while GATA-3 test was (negative) in twenty-one samples of urothelial carcinoma. Correlation of GATA-3 with other variables (age, sex, and grade) was a statistically non-significant.
Conclusions:
Conclusion: GATA-3 is an Immunohistochemical sensitive marker to diagnose urothelial carcinoma. GATA-3 expression showed non-significant relation with age, gender and histopathological parameters and its expression has been observed to be lost or reduced in substantial proportion in relation to urothelial carcinoma. This alteration or down regulation of GATA-3 is correlated with higher tumor grade and stage.
Background: urinary bladder cancer is a disturbing malignant disorder which participates about 3% to the recent development of cancer field. The etiology and pathogenesis can be related to environmental and occupational agents. Transformation of normal urothelial cell to a neoplastic one occurs through complicated sequences of molecular proceedings termed as epithelial plasticity. Aims: to analyze expression levels of GATA-3 in bladder tumor tissues and to prove a relation between expression of GATA-3 and clinicopathological characteristics of bladder tumors, including patient age, sex, tumor grade, and muscle invasion.
Material and methods:
Materials and methods: Forty Formalin fixed paraffin embedded FFPE tissue blocks obtained from bladder tumor by transurethral resection are collected from teaching hospitals at Al-Najaf governorate. Those blocks are stained by using hematoxylin and eosin stain. Histopathological features were examined and then immunostained by GATA-3.
Results:
Results: Evaluation of GATA-3 expression in urothelial carcinoma, revealed GATA-3 test was (positive) in thirty-four samples of urothelial carcinoma, while GATA-3 test was (negative) in twenty-one samples of urothelial carcinoma. Correlation of GATA-3 with other variables (age, sex, and grade) was a statistically non-significant.
Conclusions:
Conclusion: GATA-3 is an Immunohistochemical sensitive marker to diagnose urothelial carcinoma. GATA-3 expression showed non-significant relation with age, gender and histopathological parameters and its expression has been observed to be lost or reduced in substantial proportion in relation to urothelial carcinoma. This alteration or down regulation of GATA-3 is correlated with higher tumor grade and stage.
REFERENCES (33)
1.
Richters A, Aben KK, Kiemeney LA. The global burden of urinary bladder cancer: An update. World J Urol. 2020; 38:1895–904. doi: 10.1007/s00345-019-02984-4.
2.
Mushtaq J, Thurairaja R, Nair R. Bladder Cancer Surgery. 2019; 37(9): 529-37. https://doi.org/10.1016/j.mpsu....
3.
Mishra V, Balasubramaniam G. Urinary bladder cancer and its associated factors –An epidemiological overview. Indian J Med Sci 2021; 73: 239–48. doi: 10.25259/IJMS_159_2020.
4.
Agarwal H, Babu S, Rana C, Kumar M, Singhai A, Shankhwar SN, et al. Diagnostic utility of GATA3 Immunohistochemical expression in urothelial carcinoma. Indian J Pathol Microbiol. 2019; 62(2): 244–50. doi: 10.4103/IJPM.IJPM_228_18.
5.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021 May; 71(3):209-249. doi: 10.3322/caac.21660.
6.
Guo CC, Bondaruk J, Yao H, Wang Z, Zhang L, Lee S, et al. Assessment of luminal and basal phenotypes in bladder cancer.Sci Rep. 2020; 10: 9743. Article number: 9743 (2020).
7.
Wang Y, Zhang J, Wang Y, Wang S, Zhang Y, Miao Q, et al. Expression status of GATA3 and mismatch repair proteins in upper tract urothelial carcinoma. Front. Med. 2019, 13(6): 730–740 https://doi.org/10.1007/s11684....
8.
Jangir H, Nambirajan A, Seth A, Sahoo RK, Dinda AK, Nayak B, et al. Prognostic stratification of muscle invasive urothelial carcinomas using limited immunohistochemical panel of Gata3 and cytokeratin 5/6, 14 and 20. Ann Diagn Pathol. 2019; 43: Article 151397. doi: 10.1016/j.anndiagpath.2019.08.001.
9.
Wang CC, Tsai YC, Jeng YM. Biological significance of GATA3, cytokeratin 20, cytokeratin 5/6 and p53 expression in muscle-invasive bladder cancer. PLoS One. 2019; 14: Article e0221785.
10.
Pena MDCRP, Chaux A, Eich M-L Tregnago AC, Taheri D, Borhan W, et al. Immunohistochemical assessment of basal and luminal markers in non-muscle invasive urothelial carcinoma of bladder. Virchows Arch. 2019; 475: 349-356. doi: 10.1007/s00428-019-02618-5.
11.
Yuk HD, Jeong CW, Kwak C, Kim HH, Moon KC, Ku JH, et al. Clinical outcomes of muscle invasive bladder Cancer according to the BASQ classification. BMC Cancer. 2019 Sep 9; 19(1):897. doi: 10.1186/s12885-019-6042-1.
12.
Wang C, Yang S, Jin L, Dai G, Yao Q, Xiang H, et al. Biological and clinical significance of GATA3 detected from TCGA database and FFPE sample in bladder cancer patients. Onco Targets Ther. 2020 Jan 31; 13: 945–958. doi: 10.2147/OTT.S237099.
13.
Goto T, Miyamoto H. The role of estrogen receptors in urothelial cancer. Front Endocrinol (Lausanne). 2021; 12(2021), Article 643870.
14.
Saginala K, Barsouk A, Aluru JS, et al. Epidemiology of bladder cancer. Med Sci. 2020; 18(1): 15. https://doi.org/10.3390/medsci....
15.
Agarwal H, Babu S, Rana C, et al. Diagnostic utility of GATA3 immunohistochemical expression in urothelial carcinoma. Indian J Pathol Microbiol. 2019; 62(2): 244-50.
16.
Jung M, Jang I, Kim K, et al. CK14 expression identifies a basal/squamous-like type of papillary non-muscle-invasive upper tract urothelial carcinoma. Front Oncol. 2020; (10):623. http://doi:10.3389/fonc.2020.0....
17.
Jangir H, Nambirajan A, Ranjit AS, et al. Prognostic stratification of muscle invasive urothelial carcinomas using limited immunohistochemical panel of Gata3 and cytokeratin’s 5/6, 14 and 20. Ann Diagn Pathol. 2019; (43): 151397.
18.
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA. (2021) 71:209–49. 10.3322/caac.21660.
19.
Witjes JA, Bruins HM, Cathomas R et al. European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines. Eur Urol. 2021; 79:82–104.
20.
Kamoun A, de Reynies A, Allory Y, et al. A consensus molecular classification of muscle-invasive bladder cancer. Eur Urol. 2019; 77: 420–33.
21.
Bejrananda T, Kanjanapradit K, Saetang, et al J. Impact of immunohistochemistry based subtyping of GATA3, CK20, CK5/6, and CK14expression on survival after radical cystectomy for muscle-invasive bladder cancer. Sci Rep. 2021; 11: 211-86. doi: 10.1038/s41598-00628-5.
22.
Bernardo C, Monteiro FL, Direito I, et al. Association between estrogen receptors and GATA3 in bladder cancer: a systematic review and meta-analysis of their clinic pathological significance. Front Endocrinol (Lausanne). 2021; 12: 684-140. doi: 10.3389/fendo.2021.684140.
23.
Lotan Y, de Jong JJ, Liu VYT, et al. Patients with muscle-invasive bladder cancer with nonluminal subtype derives greatest benefit from platinum based neoadjuvant chemotherapy. J Urol. 2021; 207: 541–50. 10.1097/JU.0000000000002261.
24.
Guo WCC, Bondaruk J, Yao H, et al. Assessment of luminal and basal phenotypes in bladder cancer. Sci Rep. 2020; 10:9743. 10.1038/s41598-020-66747-7.
25.
Guo CC, Bondaruk J, Yao H, et al. Assessment of luminal and basal phenotypes in bladder cancer. Sci Rep. 2020; 10: 97-43. doi: 10.1038/s41598-020-66747-7.
26.
Bejrananda T, Kanjanapradit K, Saetang J, Sangkhathat S. Impact of immunohistochemistry-based subtyping of GATA3, CK20, CK5/6, and CK14 expression on survival after radical cystectomy for muscle-invasive bladder cancer. Sci Rep. 2021; 11: 21186. 10.1038/s41598-021-00628-5.
27.
Kim J, Kwiatkowski D, McConkey DJ, Meeks JJ, Freeman SS, Bellmunt J, et al. The cancer genome atlas expression subtypes stratify response to checkpoint inhibition in advanced urothelial cancer and identify a subset of patients with high survival probability. Eur Urol. 2019; 75: 961–4. 10.1016/j.eururo.2019.02.017.
28.
Sjödahl G, Abrahamsson J, Holmsten K, Bernardo C, Chebil G, Eriksson P, et al. Different responses to neoadjuvant chemotherapy in urothelial carcinoma molecular subtypes. Eur Urol. 2021; 81: 523–32. doi: 10.1016/j.eururo.2021.10.035.
29.
Taber A, Christensen E, Lamy P, Nordentoft I, Prip F, Lindskrog SV, et al. Molecular correlates of cisplatin-based chemotherapy response in muscle invasive bladder cancer by integrated multi-omics analysis. Nat Commun. 2020; 11: 4858. Article number: 4858 (2020).
30.
Kollberg P, Chebil G, Eriksson P, Sjödahl G, Liedberg F. Molecular subtypes applied to a population-based modern cystectomy series do not predict cancer-specific survival. Urol Oncol. 2019; 37: 791–9. 10.1016/j.urolonc.2019.04.010.
31.
Yoo D, Min KW, Pyo JS, Kim NY. Diagnostic and Prognostic Roles of GATA3 Immunohistochemistry in Urothelial Carcinoma. Medicina (Kaunas). 2023;59(8):1452. Published 2023 Aug 11. doi:10.3390/medicina59081452.
32.
(32) Font A, Domenech M, Benitez R, Rava M, Marques M, Ramirez JL, et al. Immunohistochemistry-based taxonomical classification of bladder cancer predicts response to neoadjuvant chemotherapy. Cancers (Basel). (2020) 12:1784. 10.3390/cancers12071784.
33.
Lin X, Zhu B, Villa C. The utility of p63, p40, and GATA-binding protein 3 immunohistochemistry in diagnosing micropapillary urothelial carcinoma. Hum Pathol. 2014; 45: 1824–1829. doi: 10.1016/j.humpath.2014.04.015.
| eISSN: | 2719-342X |
| ISSN: | 0043-5147 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
